Listen
OVITRELLE (choriogonadotropin alfa) - Assisted reproductive technologies
Opinions on drugs -
Posted on
Mar 06 2025
Reason for request
Initial inclusion
Summary of opinion
Favourable opinion for reimbursement in the treatment of:
- adult women undergoing superovulation prior to assisted reproductive technologies (ART) such as in vitro fertilisation (IVF),
- anovulatory or oligo-ovulatory adult women.
No clinical added value of the new pre-filled syringe form compared to the forms already available.
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of OVITRELLE (choriogonadotropin alfa) is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
